BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Price, Quote, News and Overview
TSX:BCT - Toronto Stock Exchange - CA1079301091 - Common Stock - Currency: CAD
BCT.CA Quote, Performance and Key Statistics
TSX:BCT (3/7/2025, 7:00:00 PM)
5.01
-0.12 (-2.34%)
The current stock price of BCT.CA is 5.01 CAD. In the past month the price decreased by -13.17%. In the past year, price decreased by -91.63%.
BCT.CA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 270.34M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 214.26M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 202.17M | ||
| TH.CA | THERATECHNOLOGIES INC | N/A | 101.16M | ||
| MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 84.29M | ||
| ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 79.22M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 77.44M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 14.18 | 66.08M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | 38.5 | 54.80M | ||
| SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 49.83M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 46.66M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 20.78M |
Related stock screener links
About BCT.CA
Company Profile
Briacell Therapeutics Corp is a CA-based company operating in Biotechnology industry. The company is headquartered in West Vancouver, British Columbia and currently employs 17 full-time employees. The company went IPO on 2006-10-12. BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
BRIACELL THERAPEUTICS CORP
Suite 300 - Bellevue Centre, 235 -15th Street
West Vancouver BRITISH COLUMBIA V7T 2X1 CA
CEO: William Williams
Employees: 16
Company Website: https://briacell.com/
Investor Relations: http://investors.briacell.com/filings-and-shareholder-info
Phone: 16049211810
BRIACELL THERAPEUTICS CORP / BCT.CA FAQ
What is the stock price of BRIACELL THERAPEUTICS CORP today?
The current stock price of BCT.CA is 5.01 CAD. The price decreased by -2.34% in the last trading session.
What is the ticker symbol for BRIACELL THERAPEUTICS CORP stock?
The exchange symbol of BRIACELL THERAPEUTICS CORP is BCT and it is listed on the Toronto Stock Exchange exchange.
On which exchange is BCT.CA stock listed?
BCT.CA stock is listed on the Toronto Stock Exchange exchange.
What is BRIACELL THERAPEUTICS CORP worth?
BRIACELL THERAPEUTICS CORP (BCT.CA) has a market capitalization of 18.59M CAD. This makes BCT.CA a Nano Cap stock.
How many employees does BRIACELL THERAPEUTICS CORP have?
BRIACELL THERAPEUTICS CORP (BCT.CA) currently has 16 employees.
What are the support and resistance levels for BRIACELL THERAPEUTICS CORP (BCT.CA) stock?
BRIACELL THERAPEUTICS CORP (BCT.CA) has a resistance level at 6.3. Check the full technical report for a detailed analysis of BCT.CA support and resistance levels.
Should I buy BRIACELL THERAPEUTICS CORP (BCT.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BCT.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BCT.CA, evaluating the profitability, health, valuation and growth aspects
- BRIACELL THERAPEUTICS CORP (BCT.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRIACELL THERAPEUTICS CORP (BCT.CA) Sales and EPS estimates to see what analysts future expectations are.
- BRIACELL THERAPEUTICS CORP (BCT.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRIACELL THERAPEUTICS CORP (BCT.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Chart to make your own analysis
- BRIACELL THERAPEUTICS CORP (BCT.CA) Latest news and press-releases to stay up to date.
Does BRIACELL THERAPEUTICS CORP (BCT.CA) stock pay dividends?
BCT.CA does not pay a dividend.
When does BRIACELL THERAPEUTICS CORP (BCT.CA) report earnings?
BRIACELL THERAPEUTICS CORP (BCT.CA) will report earnings on 2025-06-12.
What is the Price/Earnings (PE) ratio of BRIACELL THERAPEUTICS CORP (BCT.CA)?
BRIACELL THERAPEUTICS CORP (BCT.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.1).
BCT.CA Technical Analysis
BCT.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BCT.CA. Both the profitability and financial health of BCT.CA have multiple concerns.
BCT.CA Financial Highlights
Over the last trailing twelve months BCT.CA reported a non-GAAP Earnings per Share(EPS) of -7.1. The EPS decreased by -186.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.59% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCT.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to BCT.CA. The Buy consensus is the average rating of analysts ratings from 5 analysts.